Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Argo Biopharmaceutical Co., Ltd. is a clinical-stage biotechnology company focused on developing next-generation siRNA therapies and will present at the upcoming J.P. Morgan Healthcare Conference [1]. Group 1: Company Overview - Argo Biopharma is dedicated to creating RNAi therapeutics aimed at improving treatment options for patients globally [2]. - The company has developed a diverse pipeline of RNAi molecule candidates that target various indications, including cardiovascular diseases, viral infections, metabolic conditions, and specialty/rare diseases [2]. - Currently, Argo Biopharma has six RNAi candidates in clinical development [2].